When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
The decision to place Novo Nordisk on the Catalyst Watch list underscores a short-term bullish outlook, distinct from the firm’s longer-term “overweight” rating. The Catalyst Watch designation flags ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback